Research · Sep 3, 2026
[JAZZ] Jazz Pharmaceuticals Thesis 2026: Xywav Sleep Franchise Drives Epidiolex Oncology Diversification
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) FY2025 revenue ~$4.05-4.30B (+0-7%) with adj. EPS ~$19.50-21.50 reflecting continued post-2024 ~$1.55-1.70B aggregate Xywav (calcium/magnesium/potassium oxybates) revenue (~38%+ aggregate revenue mix; selected primary narcolepsy + idiopathic hypersomnia treatment) + selected continued post-2024 ~$1.20-1.30B aggregate Epidiolex (cannabidiol) revenue (~28% aggregate revenue mix; selected primary Lennox-Gastaut + Dravet + tuberous sclerosis pediatric epilepsy treatment) + selected continued post-May 2021 ~$7.2B aggregate GW Pharmaceuticals acquisition completion + selected continued post-2024 selected various Rylaze + Zepzelca + Vyxeos + selected various oncology + selected various pipeline under continued President + CEO Bruce Cozadd since 2009 (~16-year tenure as Jazz Pharmaceuticals Founder + CEO). One of the world's leading sleep + oncology + pediatric epilepsy specialty pharmaceutical companies. Founded 2003 as Jazz Pharmaceuticals in Palo Alto California by Bruce Cozadd + selected various Alza founders (~22-year heritage); selected post-2007 NASDAQ listing IPO; selected post-July 2012 Azur Pharma + Ireland tax inversion; selected post-July 2020 Xywav FDA approval; selected post-May 2021 ~$7.2B aggregate GW Pharmaceuticals acquisition completion. Headquartered in Dublin Ireland; ~3,500+ employees globally with ~$4.05-4.30B revenue. Two primary therapeutic segments: Sleep + Pediatric Epilepsy (~70%+ ~$2.85-3.05B), Oncology + Hematology (~25-30% ~$1.0-1.2B). Geographic mix: US ~85%+ + Europe + selected various ~15%. Xywav sleep franchise: ~$1.55-1.70B aggregate Xywav revenue FY2025; ~50%+ aggregate US oxybate market share leadership. Epidiolex + Oncology diversification: ~$1.20-1.30B aggregate Epidiolex revenue; selected post-May 2021 ~$7.2B GW Pharmaceuticals acquisition; Rylaze + Zepzelca + Vyxeos + selected various oncology. President + CEO Bruce Cozadd since 2009 (~16-year tenure); CFO Renee Galá. Capital + cash position + deleveraging: ~$300-500M aggregate FY2024-2025 buyback program (~$200-300M aggregate FY2025); aggregate capital return ~$200-300M; ~$2.5-3.0B aggregate cash + investments balance; net leverage ratio ~1.7-2.2x; investment-grade Ba2/BB+ credit rating (post-2024 upgrade pathway). FY2026 thesis: Xywav sleep franchise + Epidiolex pediatric epilepsy + Oncology diversification + selected post-May 2021 GW Pharmaceuticals integration + ~$2.5-3.2B aggregate cash + investments balance + ~$300-400M aggregate annual buybacks + selected continued post-May 2021 deleveraging + selected potential post-deleveraging dividend initiation. Risks: Xywav generic erosion + Avadel Lumryz + Harmony Wakix competition, Epidiolex commercialization sustainability, GW Pharmaceuticals integration + deleveraging, US payer + reimbursement risk.